WIXLIB

GSK Corporate Responsibility Report 2012Our approachHealth for allOur behaviourOur peopleOur planet6Governance and engagementQ&A with the Chairman and Chief Executive OfficerDespite a challengingenvironment, we havedelivered resilientperformance, enhancedreturns to shareholders,and made substantivemoves to increase accessand transparency.Q How is operating responsibly tiedin with GSK’s commercial success?AW Our commercial success is inextricablylinked to operating in a trustworthy andresponsible way. Our strategy is to generatediversified sales growth, develop innovativeproducts and make these accessible to as manypeople who can benefit from them as possible.And we will do this in a way that is alignedwith our values of transparency, respect,integrity and always putting patients orconsumers needs first. By doing this we willbring positive returns to our shareholders andbenefits to patients and wider society. This isreal shared value.Q What progress is the companymaking to deliver long-term value?AW R&D made significant progress in 2012with six new products now under regulatoryreview. Over the next three years, GSK has thepotential to launch around 15 new productsglobally – a good platform for growth andpatient benefit. We have also continued todevelop our portfolios and expand ourfootprint in emerging markets.Sir Christopher GentChairmanSir Andrew WittyChief Executive OfficerQ Where did GSK see strongresponsible performance in 2012?AW Our 2012 commitments to increasetransparency of clinical trials data demonstratethe values at the heart of our company. Inaddition to sharing information about thedesign and results of all of our clinical trials,we are setting up a new system to allowresearchers to request access to anonymisedpatient-level data. People participate in ourresearch trials in the hope they might helpbring advances in healthcare. Our plansrecognise this commitment and reflect ourdesire to ensure their contribution can leadto health gains. Building on this, we were alsothe first pharmaceutical company to sign upto the AllTrials campaign for clinical trialtransparency and to commit to make ourClinical Study Reports publicly available.We hope these initiatives will help furtherscientific understanding, inform medicaljudgement and ultimately improve patient care.2012 also saw another milestone in ourjourney towards a malaria vaccine, publishinglate stage clinical trial results showing that ourRTS,S vaccine candidate can help protectAfrican infants against malaria.CG I was delighted to see GSK recognised asfirst in the Access to Medicines Index in 2012,sustaining the top spot from previous years.Such independent and credible assessment ofour work to improve access to medicines andvaccines lets us know we are on the right track.In July 2012, the Group successfully resolveda series of long-standing legal matters withthe US Government. These primarily relatedto historical sales and marketing practices.The Board recognises that these matters donot reflect the company that GSK is today.The company continues to take action at alllevels to improve procedures for compliance,marketing and selling and embed a valuesbased culture in GSK.Q What issues will be addressed in2013 and beyond?AW We will see through the implementationof our commitments on transparencyof clinical trials data, continue with ourcommitments on pricing, and look to furtherharness manufacturing technologies toimprove our carbon footprint.Q How does the Board assess GSK’sresponsible performance?CG The Corporate Responsibility Committee(CRC), which I chair, meets four times a yearand receives reports on progress in the fourareas outlined in this report – health for all,our behaviour, our people and our planet. TheBoard continues to constructively challenge andadvise on the executive team’s thinking anddecisions as they seek to deliver the company’sstrategic priorities in a responsible way.Q Why is GSK setting longer-termcommitments this year?AW These new commitments signal GSK’s longterm and strategic intent to play our part andcreate shared value. They span our entirebusiness, are fully aligned to our strategyand build on our established track record.CG It is important that those outside thecompany can understand our priorities andcan hold us to account effectively. These newcommitments do that, while helping uscommunicate how we are delivering.

GSK Corporate Responsibility Report 2012Our approachHealth for allOur behaviourOur peopleOur planet7Governance and engagementOur progress in 2012We report our responsiblebusiness performanceeach year as part of ourcommitment to transparency.Our approach and theprogress we are makingto operate our businessresponsibly is reportedacross four areas.Shared value progress 2012Health for allOur behaviourTopped the Access to MedicinesIndex for the third time.1stSee page 18Over the next three years we have thepotential to bring around 15 newmedicines and vaccines to patients.15See page 14Delivered our vaccine to the world’slargest mass vaccination programmeagainst pneumococcal disease.The GAVI-led introduction of thepneumococcal vaccine in Pakistan isexpected to protect up to 4.8 millionchildren a year.See page 19m4.8Our peopleCommitted to provide accessto anonymised trial data frompublished clinical trials of ourauthorised medicines.Maintained a rate of 85% ofemployees saying they are proudto work at GSK.See page 57See page 41This is in addition to disclosing theresults of our research on our publiclyaccessible Clinical Studies Registerwebsite which receives an average ofalmost 11,000 visitors a month.See page 3311,000Revised our Code of Conduct.Our planet85%Enabled 91 employee volunteersto work in 22 countries throughour PULSE assignments.See page 5491Increased the proportion of womenin management to 40%, up from39% in 2011.See page 35See page 5540%Despite reducing our carbon fromenergy use by 15% since 2010, our totalcarbon footprint (excluding that fromraw materials) has increased by 7% from2010 driven by higher inhaler sales.i 7%See page 64Reduced water consumption in ourown operations by 14% comparedto 2010.See page 66Cut total waste by 9%compared to 2010.See page 6614%ii9%External recognitionWe have received external recognition for our responsible business approach.Vigeo World,European and UK indexesRanked second in the worldfor environmental, social andgovernance in this new ranking.FTSE4Good IndexAccess to Medicines IndexWe have been in theFTSE4Good Index since 2004.Ranked top for the third time.Carbon DisclosureProject Leadership IndexDow JonesSustainability IndexFour consecutive years in theFTSE 350 Carbon DisclosureLeadership index (2009-2012)and highest scoring healthcarecompany in the FTSE 350 (2012).We are disappointed notto be included in the DowJones Sustainability Indexesthis year and are reviewingour performance againstthe criteria for inclusion.

GSK Corporate Responsibility Report 2012Our approachHealth for allCommitmentsmoving forwardDuring 2012, we developedforward-looking commitmentsthat reflect global healthneeds and are alignedwith our strategic prioritiesand values.These commitments1 were developedfollowing significant engagement from acrossthe business. We also consulted a broad rangeof external stakeholders such as global publichealth experts, non-governmental organisationsand socially responsible investors. Thesecommitments will guide our work in theseareas in the coming years, enabling us to buildon previous achievements and to measure andcommunicate our progress more effectively.We will begin reporting progress against ournew commitments in our next report.Our behaviourHealth for allOur people Invest in the development of vaccines that don’t require continuousrefrigeration, making distribution easier and less expensive. Continue to build a core range of products and formats to better meetthe needs of people across the globe, including those less able to accessand afford our products. Further embed our flexible pricing strategy and innovative businessmodels for our prescription medicines and vaccines, to increase usageamong those less able to access and afford our products. Continue to invest in innovative cross-sector partnershipsto reduce child mortality.Putting the interests of patients andconsumers first, driven by our values ineverything we do and backed by robustpolicies and strong compliance processes. C ontinue to drive a values-based approach to sales and marketing practicesacross the world, with the interests of consumers and patients at its core. Continue to ensure the interests and safety of patients and consumersare of paramount importance in the way we design and undertakeour clinical trials, our product quality assurance and our monitoring andreporting of adverse events in ongoing product usage. Rigorously challenge the need for animal studies and work to minimisethe impact on animal welfare, by investing in the development of alternativestudies and sharing animal-based data. Address the UN Guiding Principles on Human Rights and Business acrossour own operations and our supplier relationships. Be as transparent as possible with our clinical trial data, including publishingclinical study reports (without patient-level data) for all outcome trials ofmedicines conducted by GSK and, within an appropriate process, makingavailable to researchers access to anonymised patient-level data to furtherscientific enquiry.1 All commitments are subject to any significantlegal or intellectual property restraints.Governance and engagementInnovating to address currently unmet health needs;improving access to our products, irrespective of where people live or their ability to pay;and controlling or eliminating diseases affecting the world’s most vulnerable people. Adapt the open innovation R&D model, currently used for diseasesof the developing world, to apply to other areas of great unmetmedical need and scientific challenge, including infectious diseaseand Alzheimer’s disease, by 2015.Our behaviourOur planet8 Demonstrate that all GSK interactions with patient advocacy groups andpolitical stakeholders are conducted appropriately, ethically and transparently. Continue to work with partners to support the strengthening of healthcareinfrastructure. We anticipate this could improve access to healthcare for20 million under-served people by 2020 (vs 2012). Through ViiV Healthcare, continue to increase access to our medicines andcare for adults and children living with HIV around the world. We will helpWHO and UNAIDS achieve their goal of reaching 15 million people globallywith antiretroviral treatment by 2015. Build on our 30-year commitment to contribute to the fight against malariathrough continued R&D investment and partnerships on the ground. Help eliminate and control ten neglected tropical diseases that affect1.4 billion people, by 2020 – including the elimination of lymphatic filariasis,through our continued investment in R&D, ongoing product donations andour contribution to the London Declaration on Neglected Tropical Diseases. Continue to support the WHO objective of eradicating polio by 2018by providing vaccines to UNICEF until this is achieved.Our peopleEnabling our people to thriveand develop as individuals to deliverour mission. C ontinue to promote inclusion and diversity globally at GSK. Continue to create a working environment that inspires people to growand perform in a healthy and resilient way. Extend volunteering opportunities to bring about positive changeto communities and global health while providing individual development.Our planetGrowing our business while reducingour environmental impact across ourvalue chain. Reduce our overall carbon footprint by 25% by 2020 (vs. 2010) and havea carbon-neutral value chain by 2050. By 2020, reduce our water impact across the value chain by 20% (vs. 2010). By 2020, reduce our operational waste by 50% (vs. 2010). Build sustainable supply lines for our nutrition portfolio and work withlocal farmers to improve their agricultural practices, and improve their yields,their competitiveness and their livelihoods.

GSK Corporate Responsibility Report 2012Our approachHealth for allOur behaviourOur peopleOur planet9Governance and engagementHealth for allIn this sectionIn focusGiving children a better startin life through deworming.Read more on page 10Overview11Improving healthcare: a global challenge13Innovative science to create value for all14Access to healthcare18Diseases of the developing world24Health and well-being in our communities27HIV/AIDS30

GSK Corporate Responsibility Report 2012Our approachHealth for allOur behaviourOur peopleOur planet10Governance and engagementHealth for allWe want to make our productsaccessible and affordable for the peoplewho need them while generatingthe returns we need to invest in R&Dand grow our business.In focusGivingchildren abetter startin life throughdewormingThe need for new and existing treatments is increasing as the world’spopulation grows and ages. Many millions of people in developingcountries still have little or no access to basic healthcare and rising costsare a significant concern everywhere. We continue to evolve our businessmodel to address these global challenges and ensure our businessis sustainable.GSK contributes to improving health by developing innovative andvalued products, and supporting disease prevention. Our R&D is focusedon meeting unmet medical needs and helping to control and eliminatediseases affecting the world’s most vulnerable people.We are investing to expand our portfolio in new ways and partneringwith others to tackle issues outside our core business such as the lackof healthcare infrastructure.We aspire to be a catalyst for change beyond our company. Many ofthe changes we have made in our own business – from creating newmodels of open innovation to more flexible pricing – have alreadycontributed to wider change in the industry.GSK is playing a leading role in a globalcoalition of pharmaceutical companies,non-government organisations, governmentsand global health organisations, committedto work together to control or eliminate10 of the 17 of the WHO’s neglected tropicaldiseases by 2020.As part of this commitment, GSK will donateup to 600 million treatments of our antiparasitic treatment, albendazole, each yearto help eliminate lymphatic filariasis (LF), andup to 400 million treatments to fight intestinalworms in school age children. We havealready donated over three billion albendazoledoses to fight these two devastating diseases.Intestinal worms affect more than 1.5 billionpeople worldwide and are one of the biggestcauses of ill health in school-age children withan estimated 890 million children at risk.by controlling worms inchildren you are investingin their futureThe effects – including stomach pains, sickness,malnutrition – are painful and debilitating.Intestinal worms can cause stuntingphysical growth, and affect long-termbrain development. Infected children oftenstruggle to attend or stay alert at school,hindering their education and prospects.In 2012, we provided albendazole treatmentsfor over 120 million school age children.Deworming helps to break the cycle inthe developing world. Healthier childrenare more likely to attend school and geta better education – giving them a betterchance of getting good jobs. As theheadmistress of a local school in Ghanasays,“by controlling worms in children youare investing in their future”.

GSK Corporate Responsibility Report 2012Our approachHealth for allOur behaviourOur peopleOur planet11Governance and engagementOverview2012 at a glanceInnovative science to create value for allAccess to healthcareDiseases of the developing worldInvested 3.5 billion in global research anddevelopment. We have over 50 investigationalmedicines in development, including thosetargeting cancer, diabetes and heart disease.Delivered our vaccine to the world’s largestmass vaccination programme againstpneumococcal disease. The GAVI-ledintroduction of Synflorix in Pakistanis expected to protect up to 4.8 millionchildren a year.Initiated and joined the LondonDeclaration to control or eliminateten neglected tropical diseases by 2020.See page 14 3.5bnPut into the public domain 177 compoundsshowing promising starting points for newTB medicines, following a screening of ourentire pharmaceutical library of more thantwo million compounds.See page 17177Committed a further 5 million to theTres Cantos Open Lab Foundation, doubling itsfunding for independent research into diseasesof the developing world at GSK’s Open Lab.See page 19m4.8Since our Developing Countries and MarketAccess unit was established in 2010, thevolume of medicines we supply to LeastDeveloped Countries has increased by nearly50% from 55 million units in 2010 to82.5 million in 2012.See page 24Committed to meeting at least 30% of theGlobal Polio Eradication Initiative’s poliovaccine requirements, procured throughUNICEF and will continue to support theinitiative until every country in the worldis declared ‘polio free’.See page 25Donated our three billionth albendazoletablet to fight lymphatic filariasis andintestinal worms, and pledged to donateup to a further one billion tablets a year.See page 24Health and well-beingin our communitiesDonated 206 million to promotethe health and well-being ofcommunities through productand financial donationsSee page 27See page 18 206mHIV/AIDSSee page 17Established programmes trainingcommunity health workers in 34 LeastDeveloped Countries, meeting ourcommitment to reinvest 20% of profitsmade in those countries back intodeveloping health infrastructure.See page 2234Published late-stage clinical trialresults showing that our RTS,S vaccinecandidate can help protect Africaninfants against malaria.See page 26ViiV Healthcare submitted regulatoryapplications for the investigationalintegrase inhibitor dolutegravirand spearheaded a first-of-its-kindpublic-private partnership to producea new combination HIV medicine forpaediatric use in resource-limited settings.See page 30

GSK Corporate Responsibility Report 2012Our approachHealth for allOur behaviourOur peopleOur planetGovernance and

to do more, feel better and live longer. This report describes the progress we are making and how we are operating our business responsibly. About GSK Front cover image We donated anti-parasitic treatments for over 120 million school-age children in the developing world in 2012, helping to combat the effects of intestinal worms and the cycle